Syqe Medical Showcases How Microdosing Cannabis Relieves Pain via Clinical Study

Israel-based med-tech firm Syqe Medical has just finished conducting the first-ever clinical trial that proves THC inhaled in precise and low levels can relieve pain without bringing about the other side effects of consuming marijuana. THC is the primary psychoactive ingredient in cannabis.

What Did the Study Involve?

Published in the European Journal of Pain, the Syqe Medical study is the first to scientifically confirm that cannabis micro-dosing, which involves using low doses of the active compounds in marijuana, really works against pain. Even if widely acclaimed to do so, until now, cannabis hasn’t been scientifically proven to be safe for use or to provide health benefits. The Syqe study was double-blind, placebo-controlled, and multi-dose, also conducted at the Israeli Rambam Medical Center. It looked at THC levels in the blood, psychoactivity, cognitive functions, and pain relief.

How Much THC is Needed to Relieve Pain?

According to the study’s results, only 500 micrograms of THC are enough to relieve pain in a very efficient manner. Syqe test subjects taken 3 to 4 THC inhalations a day, each of these inhalations being of 500 micrograms of THC. Typically, cannabis patients consume 1 gram of THC at 15% a day. This is 150,000 micrograms of the compound. However, the Syqe study revealed that dramatically reduced doses are as efficient. Here’s what Syqe’s CEO, Perry Davidson, said about the study:

“This study is the first to show that human sensitivity to THC is significantly greater than previously assumed, indicating that if we can treat patients with much higher precision, lower quantities of the drug will be needed, resulting in fewer side effects and an overall more effective treatment. The Syqe drug delivery technology is also applicable to opioids and other compounds that, while potentially effective, are notoriously associated with dangerous side effects. The introduction of a tool to prescribe medications at such low doses with such high resolution may allow us to achieve treatment outcomes that previously were not possible.”

Syqe Has Its Own THC Inhaler

Syqe develops and sells the Syqe Selective-Dose Inhaler that’s marketed in the country of Israel by Teva, a pharmaceutical giant. This inhaler allows patients and doctors to select with precision the microgram THC levels that have to be inhaled. The Syqe platform uses the most bioavailability-enhancing tech and selective dosing measures. Furthermore, the company is now waiting for its products to get approved in Europe. Once the study is released, it surely has the FDA allowing Syqe products to enter the North American market very soon.